Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pieńkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering Committee and Investigators. Piccart M, et al. Among authors: toi m. J Clin Oncol. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4. J Clin Oncol. 2021. PMID: 33539215 Free article. Clinical Trial.
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y, et al. Toi M, et al. Cancer. 1992 Nov 15;70(10):2475-83. doi: 10.1002/1097-0142(19921115)70:10<2475::aid-cncr2820701014>3.0.co;2-p. Cancer. 1992. PMID: 1423177 Clinical Trial.
The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial.
Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M, Enomoto K, Watanabe H, Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T, Monden Y, Hattori T, Nomura Y, Sugimachi K, Hirata K, Nakazato H, Miura S, Morimoto T, Asaishi K, Kimijima I, Ota J, Sonoo H, Yamaguchi S; 5'-BC Study Group (5'-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group). Tominaga T, et al. Among authors: toi m. Int J Oncol. 2002 Mar;20(3):517-25. Int J Oncol. 2002. PMID: 11836563 Clinical Trial.
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O. Tominaga T, et al. Among authors: toi m. J Clin Oncol. 2003 Mar 15;21(6):991-8. doi: 10.1200/JCO.2003.06.014. J Clin Oncol. 2003. PMID: 12637462 Clinical Trial.
[Trastuzumab treatment for breast cancer].
Yamashiro H, Toyama K, Bando H, Saji S, Toi M. Yamashiro H, et al. Among authors: toi m. Nihon Rinsho. 2004 Jul;62(7):1305-11. Nihon Rinsho. 2004. PMID: 15283148 Japanese.
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Tominaga T, Kimura M, Asaga T, Yoshida M, Awane H, Koyama H, Takatsuka Y, Mitsuyama S, Ikeda T, Ogita M, Aoyama H, Sano M, Abe R, Nishi T, Wada T, Danno M, Toi M, Takashima S. Tominaga T, et al. Among authors: toi m. Oncol Rep. 2004 Oct;12(4):797-803. Oncol Rep. 2004. PMID: 15375502 Clinical Trial.
Early breast cancer.
Suzuki T, Toi M, Saji S, Horiguchi K, Aruga T, Suzuki E, Horiguchi S, Funata N, Karasawa K, Kamata N. Suzuki T, et al. Among authors: toi m. Int J Clin Oncol. 2006 Apr;11(2):108-19. doi: 10.1007/s10147-006-0564-7. Int J Clin Oncol. 2006. PMID: 16622745 Review.
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T. Saeki T, et al. Among authors: toi m. J Clin Oncol. 2007 Feb 1;25(4):411-7. doi: 10.1200/JCO.2006.08.1646. Epub 2006 Dec 18. J Clin Oncol. 2007. PMID: 17179098 Clinical Trial.
Improving the efficacy of trastuzumab in breast cancer.
Suzuki E, Toi M. Suzuki E, et al. Among authors: toi m. Cancer Sci. 2007 Jun;98(6):767-71. doi: 10.1111/j.1349-7006.2007.00455.x. Epub 2007 Apr 12. Cancer Sci. 2007. PMID: 17428260 Free article. Review.
769 results